Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0989341
Funder
Australian Research Council
Funding Amount
$690,000.00
Summary
Advanced NanoBiomaterials Imaging Facility. The convergence of nanotechnology with biotechnology offers unprecedented opportunities to prepare nanomaterials with defined structure and function on the nanometre scale. However, the small length scales involved in nanomaterials present challenges in their characterisation, and in turn, their interaction with biological systems. The Advanced NanoBiomaterials Imaging Facility will provide state-of-the-art equipment for examining the properties of nan ....Advanced NanoBiomaterials Imaging Facility. The convergence of nanotechnology with biotechnology offers unprecedented opportunities to prepare nanomaterials with defined structure and function on the nanometre scale. However, the small length scales involved in nanomaterials present challenges in their characterisation, and in turn, their interaction with biological systems. The Advanced NanoBiomaterials Imaging Facility will provide state-of-the-art equipment for examining the properties of nanomaterials and their interaction with biosystems. The equipment will facilitate the development of new materials that are expected to underpin advances in drug delivery, diagnostics and implant devices, further strengthening Australia's strong reputation in these areas.Read moreRead less
Discovery Early Career Researcher Award - Grant ID: DE140101553
Funder
Australian Research Council
Funding Amount
$395,220.00
Summary
A flexible virus-like particle delivery platform for next-generation vaccines. Murine polyomavirus (MPyV) capsid proteins self-assemble into spherical protein shells approximately 45 nm in diameter. Such virus-like particles (VLPs) are of considerable interest as bionanotechnological tools. The unique flexibility provided by MPyV VLPs will be exploited by exploring the ability of the interior cavity to retain bioactive cargos while engineering novel functionality on the exterior surface by 'mix- ....A flexible virus-like particle delivery platform for next-generation vaccines. Murine polyomavirus (MPyV) capsid proteins self-assemble into spherical protein shells approximately 45 nm in diameter. Such virus-like particles (VLPs) are of considerable interest as bionanotechnological tools. The unique flexibility provided by MPyV VLPs will be exploited by exploring the ability of the interior cavity to retain bioactive cargos while engineering novel functionality on the exterior surface by 'mix-and-match' assembly of VLPs from modified components. As a proof of concept for next-generation vaccines that stimulate much needed, broadly protective responses against infectious diseases, model antigens will be delivered to specific immune cells using this nano-container.Read moreRead less
Disulfide Cross-linked Hollow Polymer Capsules for Drug Delivery. The project is expected to deliver an un-paralleled drug delivery opportunity which will benefit the pharmaceutical industry, biomedical science and biotechnology. Young scientists will be trained bringing about skilled workers for Australian science and industry. The project will build on the existing as well as establish new collaborations between scientific institutions and industry. The project will result in novel intellectua ....Disulfide Cross-linked Hollow Polymer Capsules for Drug Delivery. The project is expected to deliver an un-paralleled drug delivery opportunity which will benefit the pharmaceutical industry, biomedical science and biotechnology. Young scientists will be trained bringing about skilled workers for Australian science and industry. The project will build on the existing as well as establish new collaborations between scientific institutions and industry. The project will result in novel intellectual property on which new technologies and spin-off companies will emerge, leading to increased employment opportunities in Australia and investment in Australian science and industry.Read moreRead less
Putting an end to hospital-borne infection with micronebulisation of lung-safe disinfectants. Dangerous infections are unfortunately common in hospitals, established and retransmitted via surfaces and handheld items, representing a leading contributor to death worldwide, and potentially a far more serious problem to come as antimicrobial resistance worsens. The project aims to exploit a newly discovered and unique low power nebulisation technology to nebulise a strongly antiviral, antibacterial ....Putting an end to hospital-borne infection with micronebulisation of lung-safe disinfectants. Dangerous infections are unfortunately common in hospitals, established and retransmitted via surfaces and handheld items, representing a leading contributor to death worldwide, and potentially a far more serious problem to come as antimicrobial resistance worsens. The project aims to exploit a newly discovered and unique low power nebulisation technology to nebulise a strongly antiviral, antibacterial and antifungal agent, triethylene glycol that is too viscous to do so by any other known method. Through refinement and engineering of the technology via this project, handheld and room-based continuously operating nebulisers will produce continuous microdroplet mists of these pathogen-killing agents that deposit on surfaces throughout a hospital.Read moreRead less
Improving immune response to vaccines by selective targeting of epithelial regions with the Nanopatch. Vaccination protects us from infections like measles and flu. In principle, it could protect us from all diseases, even from skin cancer and arthritis. In practice, however, vaccines to diseases like cancer have largely proved ineffective. One problem is that we don't really understand how the body's immune system responds to vaccination. Our aim, therefore, is to investigate changes in the imm ....Improving immune response to vaccines by selective targeting of epithelial regions with the Nanopatch. Vaccination protects us from infections like measles and flu. In principle, it could protect us from all diseases, even from skin cancer and arthritis. In practice, however, vaccines to diseases like cancer have largely proved ineffective. One problem is that we don't really understand how the body's immune system responds to vaccination. Our aim, therefore, is to investigate changes in the immune system when a vaccine enters the skin, as might happen by injection. Experimenting with laboratory mice and a special vaccine-injecting Nanopatch that is attached to each mouse's ear, we are starting to understand how a vaccine affects the immune cells in the skin. In the future we plan to apply this knowledge to improve vaccination in people.Read moreRead less
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0989471
Funder
Australian Research Council
Funding Amount
$300,000.00
Summary
Facility for innovation in structural biomaterials engineering. Biomaterials are used in a diverse range of environments that impact on the way that all Australians live. The Facility for Innovation in Structural Biomaterials Engineering will greatly assist researchers to undertake cross-disciplinary projects aimed at improving human health eg. smart materials that assist stem cell therapies for treating deafness and spinal cord injuries, as well the way we live eg. more durable building materia ....Facility for innovation in structural biomaterials engineering. Biomaterials are used in a diverse range of environments that impact on the way that all Australians live. The Facility for Innovation in Structural Biomaterials Engineering will greatly assist researchers to undertake cross-disciplinary projects aimed at improving human health eg. smart materials that assist stem cell therapies for treating deafness and spinal cord injuries, as well the way we live eg. more durable building materials for a sustainable national infrastructure. The facility will help Australia remain at the forefront of these high priority areas and see both individuals and industry benefit from advanced biomaterial products.Read moreRead less
Optimising the body's immune response with a Nanopatch that delivers biomolecules to the skin. The team is developing a new improved way to vaccinate against deadly infectious diseases such as influenza and malaria. They believe their Nanopatch technology will boost the power of seasonal influenza vaccination and could even solve vaccine shortages in an influenza pandemic. This is because the Nanopatch needs much less vaccine per person than a conventional syringe. They also predict that vaccine ....Optimising the body's immune response with a Nanopatch that delivers biomolecules to the skin. The team is developing a new improved way to vaccinate against deadly infectious diseases such as influenza and malaria. They believe their Nanopatch technology will boost the power of seasonal influenza vaccination and could even solve vaccine shortages in an influenza pandemic. This is because the Nanopatch needs much less vaccine per person than a conventional syringe. They also predict that vaccines delivered with a Nanopatch will require less refrigeration than conventional vaccines and can be safely administered by individuals without medical training, making the benefits of vaccination accessible to more people more cheaply, even in remote areas.Read moreRead less
Micro-nanoprojection patches for minimally-invasive and targeted delivery of genes and drugs to skin cells: from concept to technology platform. This project will address key science questions on the recently patented micro-nanoprojections patch, establishing it in Australia as a world leading technology in the rapidly growing and important field of gene and drug delivery. Unique internationally-competitive science outcoumes and research training will be generated at the interfaces between bioen ....Micro-nanoprojection patches for minimally-invasive and targeted delivery of genes and drugs to skin cells: from concept to technology platform. This project will address key science questions on the recently patented micro-nanoprojections patch, establishing it in Australia as a world leading technology in the rapidly growing and important field of gene and drug delivery. Unique internationally-competitive science outcoumes and research training will be generated at the interfaces between bioengineering, nanotechnology, pharmaceutical science and immunology. Ultimately, the project will allow improved treatment of major diseases (e.g. vaccination and immunotherapy of asthma). Achieving these health benefits by commercial pathways is expected to benefit the Australian community and emerging Biotechnology industry-creating highly valued career opportunities for Australians.Read moreRead less